Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Emergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial Results
November 7, 2016 4:16 PM ESTGAITHERSBURG, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2016.
FINANCIAL HIGHLIGHTS
The following financial highlights reflect Emergents financial performance from Continuing Operations and exclude the impact of the operations associated with the Companys former biosciences business which was spun-off into a separate publicly traded company, Aptevo Therapeutics Inc., on August 1, 2016.
Total revenues from continuing operations: Q3 2016 of $142.9 million; nine months 2016 of $337.1 millionGAAP net income from continuing operations: Q3 2016... More